Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: AbbVie is conducting a study titled ‘Prospective Multi-country, Real-world, Multi-arm Study of Treatment Persistence With RISankizumab in Psoriatic Arthritis (PERIS).’ The study aims to evaluate the long-term usage and effectiveness of risankizumab compared to other advanced therapies in managing psoriatic arthritis (PsA) in daily clinical practice. This research is significant as it seeks to provide real-world insights into treatment persistence for PsA, a condition characterized by joint swelling and stiffness linked to psoriasis.
Intervention/Treatment: The study tests risankizumab, an approved drug for PsA, against other biologic disease-modifying antirheumatic drugs (bDMARDs). Participants will receive these treatments as per local medical guidelines, focusing on their effectiveness and persistence in real-world settings.
Study Design: This observational study follows a cohort model with a prospective time perspective. It involves approximately 900 to 1200 participants across 15 countries, with a 2:1 allocation ratio between those receiving risankizumab and those on other bDMARDs. The study is designed to observe treatment outcomes over 24 months without additional participant burden.
Study Timeline: The study began on January 31, 2025, with the latest update submitted on July 18, 2025. These dates are crucial as they mark the study’s progression and ongoing recruitment status, indicating active data collection and analysis phases.
Market Implications: The study’s findings could significantly impact AbbVie’s stock performance by potentially enhancing the market position of risankizumab in PsA treatment. Positive results may boost investor confidence and influence competitive dynamics within the pharmaceutical industry, particularly among companies developing similar therapies.
The study is currently ongoing, with further details available on the ClinicalTrials portal.